OTCMKTS:CYDY CytoDyn - CYDY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.34 -0.03 (-8.09%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.33▼$0.3850-Day Range$0.24▼$0.4252-Week Range$0.15▼$1.26Volume1.41 million shsAverage Volume1.94 million shsMarket Capitalization$285.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort Interest About CytoDyn (OTCMKTS:CYDY) StockCytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.Read More Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address CYDY Stock News HeadlinesFebruary 27, 2023 | forbes.comA Court Case With High Implications For The Tech Sector And Inflation Still Higher Than Expected - Forbes AI Newsletter February 25thJanuary 15, 2023 | nz.finance.yahoo.comCytoDyn Inc. (CYDY) stock historical prices & data – Yahoo FinanceMarch 21, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.December 31, 2022 | seekingalpha.comCytoDyn: There Seems To Be No RedemptionDecember 23, 2022 | finance.yahoo.comCytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEONovember 22, 2022 | finance.yahoo.comCytoDyn to Host R&D Update on Wednesday, December 7, 2022October 20, 2022 | finance.yahoo.comCytoDyn Announces Appointment of Additional Directors with Industry ExperienceOctober 20, 2022 | globenewswire.comCytoDyn Announces Appointment of Additional Directors with Industry Experience - GlobeNewswireMarch 21, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.October 13, 2022 | streetinsider.comForm 10-Q/A CytoDyn Inc. For: Aug 31 - StreetInsider.comSeptember 8, 2022 | finance.yahoo.comCytoDyn Inc. (CYDY)August 24, 2022 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY - GlobeNewswireAugust 24, 2022 | seekingalpha.comCytoDyn: It Only Takes One Hit (OTCMKTS:CYDY) - Seeking AlphaAugust 9, 2022 | benzinga.comBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of CytoDyn Inc. (CYDY) Investigation - BenzingaJuly 14, 2022 | bizjournals.com5 things to know: Celebrating Genny Nelson's life - Portland Business Journal - The Business JournalsJuly 13, 2022 | globenewswire.comCytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President - GlobeNewswireJuly 13, 2022 | finance.yahoo.comCytoDyn Appoints Cyrus Arman, Ph.D., MBA, as PresidentJune 22, 2022 | globenewswire.comCytoDyn to Hold Webcast to Provide a Quarterly Company Update - GlobeNewswireJune 13, 2022 | seekingalpha.comCytoDyn Stock: Nearly Impossible To Revive This Company - Seeking AlphaMay 23, 2022 | finance.yahoo.comCytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer - Yahoo FinanceMay 23, 2022 | finance.yahoo.comCytoDyn Announces Resolution of Legal Dispute with Former Chief Medical OfficerMay 13, 2022 | finance.yahoo.comCytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific AdvisorApril 12, 2022 | benzinga.comCytoDyn Announces Publication of Peer-Reviewed Paper, "Suppression of Human and Simian Immunodeficie - BenzingaApril 12, 2022 | globenewswire.comCytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species” - GlobeNewswireApril 12, 2022 | finance.yahoo.comCytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”April 12, 2022 | bizjournals.comAppeals court rules in favor of former CytoDyn CEO Nader Pourhassan in stock case - Portland Business Journal - The Business JournalsApril 7, 2022 | finance.yahoo.comGlobal Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address CYDY Company Calendar Last Earnings1/09/2023Today3/21/2023Fiscal Year End5/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIP23283M101 CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-210,820,000.00 Net MarginsN/A Pretax Margin-82,877.34% Return on EquityN/A Return on Assets-435.68% Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05 Sales & Book Value Annual Sales$270,000.00 Price / Sales1,057.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-2.62Miscellaneous Outstanding Shares838,120,000Free Float828,898,000Market Cap$285.46 million OptionableNot Optionable Beta0.27 Key ExecutivesCyrus ArmanPresidentAntonio MigliareseCFO, Secretary, Treasurer & CAOChristopher P. RecknorSenior Director-Research & DevelopmentMichael D. MulhollandSenior Vice President-FinanceCristina de LeonHead-Investor RelationsKey CompetitorsPeak PharmaceuticalsOTCMKTS:PKPHPrelude TherapeuticsNASDAQ:PRLDNGM BiopharmaceuticalsNASDAQ:NGMCara TherapeuticsNASDAQ:CARAKezar Life SciencesNASDAQ:KZRView All Competitors CYDY Stock - Frequently Asked Questions How have CYDY shares performed in 2023? CytoDyn's stock was trading at $0.2250 on January 1st, 2023. Since then, CYDY stock has increased by 51.4% and is now trading at $0.3406. View the best growth stocks for 2023 here. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) announced its earnings results on Monday, January, 9th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA). What is CytoDyn's stock symbol? CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY." How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CytoDyn's stock price today? One share of CYDY stock can currently be purchased for approximately $0.34. How much money does CytoDyn make? CytoDyn (OTCMKTS:CYDY) has a market capitalization of $285.46 million and generates $270,000.00 in revenue each year. How can I contact CytoDyn? CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The official website for the company is www.cytodyn.com. The biotechnology company can be reached via phone at (360) 980-8524 or via email at mciszewski@cytodyn.com. This page (OTCMKTS:CYDY) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.